June 18-21, 2019
Beijing, CN

Artificial intelligence meets genomics: Accelerating understanding of our genetic makeup and the use of genome editing to revolutionize medicine

This will be presented in English.

Yue Cathy Chang (TutumGene)
13:1013:50 Friday, June 21, 2019

必要预备知识 (Prerequisite Knowledge)

  • A basic understanding of AI and machine learning

您将学到什么 (What you'll learn)

  • Discover genome sequencing fundamentals
  • Learn different analysis stages of sequencing, how AI applies to each, genome editing fundamentals, and AI's role
  • Explore questions about and considerations for "optimizing" human health

描述 (Description)

Genome editing has been dubbed a top technology that could create trillion-dollar markets in the next decade. Recent advancements in the application of AI to genomic editing are accelerating a path to transform medicine through secondary analysis (variant calling) and tertiary analysis (interpretation) of the data lifecycle. This field has also sparked an intense race between China and the US for leadership in precision medicine, with investments of more than $3B in 2017 alone, a significant portion of that in China. What are we doing with AI to identify genetic variants and mutations? What impact is being made to human health? What are the existing challenges? Where are investments going toward solving these challenges?

Yue Cathy Chang explores how AI is applied to different stages of genome sequencing in identifying, decoding, and interpreting the meaning of the genome, which leads to better diagnoses and the facilitation of drug selection and therapy design based on cell DNA. You’ll learn about the efforts in stem cell and somatic editing and their potential to correct mutations as well as AI’s role in enabling more accurate editing as you contemplate questions and considerations raised in using genome editing to “optimize” human health. You’ll also discover how American and Chinese companies can collaborate to enable win-win outcomes for all.

Photo of Yue Cathy Chang

Yue Cathy Chang


Yue “Cathy” Chang is a partner at TutumGene, a technology company that aims to accelerate disease curing by providing solutions for gene therapy and regulation of gene expression. She’s a business executive recognized for sales, business development, and product marketing in high technology. Previously, she was with Silicon Valley Data Science, a startup (acquired by Apple) that provided business transformation consulting to enterprises and other organizations using data science- and engineering-based solutions; employee #1 hired by the CEO at venture-funded software startup Rocana (acquired by Splunk), where she served as senior director of business development focusing on building and growing long-term relationships, and notably increased sales leads 2x through building and managing indirect revenue channels; held multiple strategic roles at blue chip software enterprise companies as well as startups, including corporate and business development at Feedzai and Datameer; senior product management, product marketing and sales at Symantec and IBM; and strategic sourcing improvement consulting at Honeywell. Cathy holds MS and BS degrees in electrical and computer engineering from Carnegie Mellon University, MBA and MS degrees as a leaders for global operations (LGO) duel-degree fellow from MIT, and two patents for her early work in microprocessor logic design.